Condition
Hairy Cell Leukemia Variant
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Active Not Recruiting1
Recruiting1
Enrolling By Invitation1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07690761Phase 2Enrolling By Invitation
Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant
NCT04815356Phase 1Recruiting
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
NCT01841723Phase 2Active Not Recruiting
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
Showing all 3 trials